New psoriasis drug tracked for 5 years in Real-World german study
NCT ID NCT06104644
First seen Dec 26, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This study follows 550 adults in Germany with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will check how well the drug clears skin and improves quality of life over 5 years in routine medical care. The goal is to see if results from clinical trials hold up in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate, Germany
-
Local Institution - 0001
Selters, 56242, Germany
Conditions
Explore the condition pages connected to this study.